Conference Coverage

Ozanimod Is Superior to Interferon in Relapsing-Remitting MS

Neurology Reviews. 2018 January;26(1):21

 

—Erik Greb

Suggested Reading

Cohen JA, Arnold DL, Comi G, et al. Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2016;15(4):373-381.

Sørensen PS. Ozanimod: a better or just another S1P receptor modulator? Lancet Neurol. 2016;15(4):345-347.

Pages

Recommended Reading

Does Concussion Increase the Risk of MS?
MDedge Neurology
Fingolimod Reduces Annualized Relapse Rate in Pediatric MS
MDedge Neurology
Highlights From the 7th Joint ECTRIMS‑ACTRIMS Meeting
MDedge Neurology
Siponimod Improves MRI Outcomes in Patients With Secondary Progressive MS
MDedge Neurology
Interferon Beta May Reduce Mortality in MS
MDedge Neurology
What Is the Prevalence of Truly Benign MS?
MDedge Neurology
Oligoclonal Bands Could Be a Valuable Criterion for the Diagnosis of MS
MDedge Neurology
Durable Improvements in Clinical Outcomes With Alemtuzumab: Seven-Year Follow-Up
MDedge Neurology
Revised McDonald Criteria Allow Substitution for Dissemination in Time
MDedge Neurology
2017 MS Highlights: The Year in Review
MDedge Neurology

Related Articles